Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients ≥18 years of age
Histological or cytologically confirmed locally advanced, inoperable or metastatic pancreatic adenocarcinoma not amenable to curative radiotherapy or surgery
Patients must have at least one uni-dimensional measurable lesion by CT or MRI according to RECIST, Version 1.1
Resolution of all acute toxic effects of any prior local treatment to Common Terminology Criteria for Adverse Events (CTCAE) Grade \</= 1
Eastern Cooperative Oncology Group performance status (ECOG PS) \</= 2
Patient has cardiac function, within normal range, as measured by an echocardiogram
You may not be if
Known history of, or symptomatic metastatic brain or meningeal tumors
Pregnant or lactating women; women of childbearing potential not employing adequate contraception
Use of strong inhibitors or inducers of CYP3A4
Prior systemic therapy for metastatic or locally advanced, unresectable pancreatic cancer, or other malignancy
Previous gemcitabine or 5-fluorouracil (5-FU) given concurrently as radiosensitizers to radiation therapy in adjuvant intention if given within 6 months from start of study treatment
Thrombotic or embolic events such within 6 months prior to start of study treatment
